| # | Drug | Count |
|---|---|---|
| 0 | BEVACIZUMAB | 17 |
| 1 | ATEZOLIZUMAB | 13 |
| 2 | ESOMEPRAZOLE | 13 |
| 3 | ESOMEPRAZOLE MAGNESIUM | 13 |
| 4 | FLUVASTATIN | 13 |
| 5 | RAMIPRIL | 13 |
| 6 | SITAGLIPTIN | 13 |
| 7 | CISPLATIN | 6 |
| 8 | CARBOPLATIN | 5 |
| 9 | ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED RELEASE | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | RASBURICASE | 1 | 0.0004 |
| 1 | ESOMEPRAZOLE MAGNESIUM DIHYDRATE | 5 | 0.0003 |
| 2 | ATEZOLIZUMAB | 13 | 0.0003 |
| 3 | OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN | 3 | 0.0002 |
| 4 | FLUVASTATIN SODIUM | 1 | 0.0002 |
| 5 | SITAGLIPTIN | 13 | 0.0002 |
| 6 | BEVACIZUMAB | 17 | 0.0001 |
| 7 | RAMIPRIL | 13 | 0.0001 |
| 8 | CISPLATIN | 6 | 0.0001 |
| 9 | AZACITIDINE | 2 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Angiotensin Converting Enzyme Inhibitor [EPC] | 13 | 0.0001 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 17 | 0.0001 |
| 2 | CD52-directed Cytolytic Antibody [EPC] | 1 | 0.0001 |
| 3 | Platinum-based Drug [EPC] | 10 | 0.0000 |
| 4 | BCL-2 Inhibitor [EPC] | 2 | 0.0000 |
| 5 | Calcineurin Inhibitor Immunosuppressant [EPC] | 3 | 0.0000 |
| 6 | Proton Pump Inhibitor [EPC] | 13 | 0.0000 |
| 7 | Epidermal Growth Factor Receptor Antagonist [EPC] | 1 | 0.0000 |
| 8 | Nitroimidazole Antimicrobial [EPC] | 1 | 0.0000 |
| 9 | Serotonin-3 Receptor Antagonist [EPC] | 2 | 0.0000 |